Acupuncture Research on Lung Cancer Patients With Cancer Related Fatigue(CRF)
Overview
we plan to conduct this trial to find out: – If acpuncture treatment could relieve CRF among lung cancer patients receiving chemo- or radio-therapy? – How about the extent it relieves?the safety and applicability ? – What's the possible influential factor and mechanism ?
Full Title of Study: “Randomized, Double-Blind, Placebo-Controlled, Stage II Trial of Acupuncture For Lung Cancer Patients With Cancer Related Fatigue(CRF)”
Study Type
- Study Type: Interventional
- Study Design
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Primary Purpose: Treatment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Study Primary Completion Date: July 2014
Interventions
- Device: acupuncture
- once per week for 6 weeks,30 mins for each treatment and for seven main acupoints
- Device: sham acupuncture
- the same acupoints and time as in acupuncture arm, but use a Park Sham Device
Arms, Groups and Cohorts
- Active Comparator: Acupuncture
- Participants will receive 30-min sessions of true acupuncture per week after randomization for 6 weeks
- Sham Comparator: sham acupuncture
- Participants will receive 30-min sessions of sham acupuncture per week after randomization for 6 weeks.
Clinical Trial Outcome Measures
Primary Measures
- Brief Fatigue Inventory, BFI
- Time Frame: 12 months
Secondary Measures
- MDASI-C
- Time Frame: 12 months
- number of adverse events of acupuncture
- Time Frame: 24 months
- FACT-L
- Time Frame: 12 months
Participating in This Clinical Trial
Inclusion Criteria
- Patients who are pathologically/cytologically diagnosed as NSCLC and received radiotherapy with or without chemotherapy, and the last radio- or chemo-therapy must be at least 30 days prior to initiation of experimental treatment; – Participants who meet the diagnosis criteria of CRF(ICD-10 criteria); – The first time to receive acupuncture treatment; – The age is between 18 and 65 years old; – Mean baseline fatigue as measured by the Brief Fatigue Inventory (BFI) must be four or above; – ECOG performance status 0, 1 or 2. – Patients must have adequate organ functions reflected by the laboratory criteria below: neutrophil counts ≥ 1.5×109 /L, platelet count ≥ 100 x 109/L, hemoglobin ≥ 85 g/L, Serum creatinine < 2.0 mg/dL, Bilirubin < 1.5 mg/dL, ALT < 3 x normal, albumin >30g/L. – Have not taken any hypnotic, melatonin, or antidepressants within 30 days; – Willing to finish the whole observation period; – With written consent form signed by themselves. Exclusion Criteria:
- Participants in other clinical research; – Can not be pathologically or cytologically diagnosed as NSCLC; – ECOG 3~4; – Pregnant woman; – >65 or <18 years old; – Patients with evidence of any cognitive dysfunction that would limit their abilities to report fatigue; – Patients who have received acupuncture ever before; – Received surgery, immunotherapy or target therapy within one month before the recruition; – Taking warfarin or heparin, a bleeding tendency exists; – Infection, ulceration or hyperalgesia at or near the local acupoints' skin,or with active infections; – There are cerebral vascular accident history or spinal cord injury history; – Combination with other serious diseases or condition, including congestive heart failure, Unstable angina pectoris, myocardial infarction during the past six months, serious's arrhythmia, mental disorders, drug abuse, etc.; – Patients with a life expectancy < 3 months; – Patients with a past history of therapy or scheduled visits non-compliance, as determined by their treating physician.
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: 65 Years
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Fudan University
- Provider of Information About this Clinical Study
- Principal Investigator: xie jing, attending – Fudan University
- Overall Official(s)
- jing xie, MD, Principal Investigator, Fudan University
- zhen chen, MD, Study Director, Fudan University
- qiang zhi meng, MD, Study Chair, Fudan University
- Overall Contact(s)
- jing xie, MD, +86 021 64175590, isable624@163.com
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.